Universitaetsspital Basel
Universitaetsspital Basel is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
Sponsor Genzyme Corp.
- Start (EU)
- Latest update
- Estimated end
MAintenance Therapy with Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-Blinded Placebo-Controlled Multi-Center Phase III Trial, Including LOGOS (Low Grade Ovarian Cancer Sub-study)
Sponsor Swiss GO Trial Group
- Start (EU)
- Latest update
- Estimated end
A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT - physician’s choice in the treatment of newly diagnosed RMS (STHENOS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The trial enrolled 185 participants at 41 centres across Germany, France, Italy, and Spain.
- A 2022 protocol amendment enlarged the eligible population, reduced protocol complexity, and revised eligibility criteria to align with current ofatumumab and other DMT product information.
- A 2021 protocol amendment required full routine laboratory testing at every on-site visit from baseline through Month 15.
These findings describe the trial, not the service provider’s performance or responsibility.
Microdosing with a serotonergic agent for ADHD and emotion regulation: biological factors explaining and predicting treatment response
Sponsor Universiteit Maastricht
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes (PRO) in patients with relapsing multiple sclerosis (RMS) transitioning from fumarate-based RMS approved therapies or fingolimod.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) non-small cell lung cancer (NSCLC). A multicenter phase II trial.
Sponsor Swiss Group for Clinical Cancer Research
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Universitaetsspital Basel?
The 2026-10-09 snapshot links Universitaetsspital Basel to 8 distinct CTIS trials. Recorded services include EDSS certification and expert review, Laboratory services, Central Medical Reading or Imaging Reading, Clinical monitoring, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Universitaetsspital Basel?
The most frequently recorded therapeutic areas are Neurology, Immunology, Gynecology, Solid Tumor Oncology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Universitaetsspital Basel conducted?
The linked trials record locations in 24 countries, including Germany, Spain, Austria, France, Poland. These are trial locations, not confirmed office locations or countries where Universitaetsspital Basel delivered services.
What can this page tell me about Universitaetsspital Basel's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Universitaetsspital Basel. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Universitaetsspital Basel